Roivant Sciences
https://roivant.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Roivant Sciences
Almirall Views Vitiligo As Next Dermatology Opportunity
As it prepares to file lebrikizumab for atopic dermatitis, the Spanish group is looking to expand into vitiligo through a collaboration with France’s Inserm Transfert to develop topical therapies for the condition where pale patches develop on the skin caused by the lack of melanin.
Kriya Raises $270m To Scale Gene Therapy Platform, Move Into The Clinic
The start-up is built around four business units – technology, manufacturing, R&D and therapeutics – based on internal and external expertise. Kriya will take its first gene therapies into the clinic in 2023.
Finance Watch: Restructurings, Layoffs Reflect Ongoing Uncertainty In Biotech
Sio Gene, Genocea, Solid Biosciences, Saniona and Black Diamond join First Wave, Zosano, Vallon, Finch, Magenta, ProQR and Imara on the growing list of biopharma firms reducing headcount to make their cash last until valuations return to a level that may support new fundraising.
Long-Term Vitiligo Data Appear To Lay Opzelura Safety Concerns To Rest
Incyte’s topical JAK inhibitor carries a class-wide severe safety warning and cautions against chronic use, but 52-week results could ease the way for the potential vitiligo indication.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Altavant Sciences
- Alyvant
- Aruvant Sciences
- Axovant Sciences
- Cyotvant Sciences
- Datavant
- Dermavant Sciences
- Enzyvant
- Genevant
- Immunovant Sciences
- Metavant Sciences
- PhaseRx
- Respivant
- Roivant Health
- Roivant Neurosciences Ltd
- Roivant Pharma
- Roivant Sciences Ltd.
- Inc.
- Sinovant Sciences
- Sumitovant Biopharma Ltd.
- Valor Biotechnology
- Axovant Gene Therapies Ltd.